⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11861754 | 0.62 | TRPA1 (0.55) | — | |
| SCHEMBL17948230 | 0.60 | — | — | |
| SCHEMBL6363449 | 0.60 | — | — | |
| SCHEMBL31257843 | 0.60 | — | — | |
| SCHEMBL739623 | 0.56 | — | — | |
| SCHEMBL664566 | 0.56 | — | — | |
| SCHEMBL12099054 | 0.56 | — | — | |
| SCHEMBL741045 | 0.55 | — | — | |
| SCHEMBL15871033 | 0.55 | PNMT (0.33) | — | |
| SCHEMBL1991296 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230271949-A1 | GLP-1R MODULATING COMPOUNDS | ASCLETIS BIOSCIENCE CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-9758537-B2 | Compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170056428-A1 | Compounds for the Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20160361329-A1 | COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20150239838-A1 | Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| EP-2762476-A1 | 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE | Taiho Pharmaceutical Co., Ltd. (JP) | 2014-08-06 | — | — | EP | disclosed |